Response | Capecitabine (n = 51†), n (%) | 5-FU (n = 46), n (%) | p- value |
---|---|---|---|
Primary tumor | 0.658‡ | ||
Complete response | 0 (0) | 0 (0) | |
Partial response | 16 (30.7) | 13(28.2) | |
Stable disease | 35 (67.3) | 32 (69.6) | |
Progressive disease | 0 (0) | 1 (2.2) | |
Overall | 0.273‡ | ||
Complete response | 0 (0) | 0 (0) | |
Partial response | 7 (13.7) | 7 (15.2) | |
Stable disease | 10 (19.6) | 15 (32.6) | |
Progressive disease | 34 (66.7) | 24 (52.2) | |
CA 19–9 percent decrease (%) | |||
Median (range) | 38.9 (-624.1–98.9) | 39.7 (-383.4–98.6) | 0.484§ |
Mean ± SE | -1.9 ± 19.5 | 16.2 ± 15.8 | |
<40 | 29 (55.8) | 26 (56.5) | 1.000‡ |
≥40 | 23 (44.2) | 20 (43.5) |